Therefore, the induction of tumor immunity by GITR Ab is attributable to both the co-stimulatory activity of GITR on responder CD4+CD25− T cells and to a direct effect on CD4+CD25+ Tregs11–13. The gene discussed is CD4; the disease is neoplasm.